Document and Entity Information
Document and Entity Information | Apr. 15, 2021 |
Cover [Abstract] | |
Document Type | 8-K/A |
Document Period End Date | Apr. 15, 2021 |
Entity Registrant Name | AVEO Pharmaceuticals, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-34655 |
Entity Tax Identification Number | 04-3581650 |
Entity Address, Address Line One | 30 Winter Street |
Entity Address, City or Town | Boston |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02108 |
City Area Code | 857 |
Local Phone Number | 400-0101 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.001 par value |
Trading Symbol | AVEO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Description | On April 16, 2021, AVEO Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) disclosing that the Board of Directors (the “Board”) of the Company elected Dr. Kevin Cullen as a member of the Board, effective April 15, 2021. Committee assignments for Dr. Cullen were not determined as of filing of the Original Form 8-K.This Form 8-K/A is being filed to report that on June 9, 2021, the Board appointed Dr. Cullen to its Audit Committee and Compensation Committee, effective immediately. |
Amendment Flag | true |
Entity Central Index Key | 0001325879 |